Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo  >  Chugai Pharmaceutical Co Ltd    4519   JP3519400000

CHUGAI PHARMACEUTICAL CO LTD

(4519)
  Report  
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Financials (JPY)
Sales 2019 633 B
EBIT 2019 171 B
Net income 2019 127 B
Finance 2019 265 B
Yield 2019 1,38%
Sales 2020 682 B
EBIT 2020 205 B
Net income 2020 151 B
Finance 2020 300 B
Yield 2020 1,63%
P/E ratio 2019 32,1x
P/E ratio 2020 26,7x
EV / Sales2019 6,07x
EV / Sales2020 5,58x
Capitalization 4 106 B
More Financials
Company
Chugai Pharmaceutical Co. specializes in the research, development, manufacturing and marketing of drugs especially for cancers (50.5% of net sales), bones and joints diseases treatment (30.9%), and kidney diseases (7.9%). Net sales are distributed geographically as follows: Japan (81.2%),... 
Sector
Pharmaceuticals
Calendar
10/24Earnings Release
More about the company
Surperformance© ratings of Chugai Pharmaceutical Co L
Trading Rating : Investor Rating :
More Ratings
Latest news on CHUGAI PHARMACEUTICAL CO L
09/12CHUGAI PHARMACEUTICAL : Presents Results from Second Positive Global Phase III C..
BU
09/10CHUGAI PHARMACEUTICAL : Disease Awareness Website 'Let's Learn about Rheumatoid ..
AQ
09/09CHUGAI PHARMACEUTICAL : Files for Expanded Use of FoundationOne CDx Cancer Genom..
AQ
09/02CHUGAI PHARMACEUTICAL : Files for Additional Indication for Anti-HER2 Antibody D..
AQ
08/23CHUGAI PHARMACEUTICAL : Tecentriq, an Anti-PD-L1 Antibody, Receives Approval for..
AQ
07/31Chugai Continues to be listed for All ESG Indices Selected by GPIF
AQ
07/26CHUGAI PHARMACEUTICAL : Announces 2019 Half Year Results
AQ
07/26CHUGAI PHARMACEUTICAL : Organizational and Personnel Changes
AQ
07/12Japan's polarised stock market leaves few options for investors
RE
07/10CHUGAI PHARMACEUTICAL : Further Clinical Data including Long-Term Follow-up for ..
AQ
More news
Analyst Recommendations on CHUGAI PHARMACEUTICAL CO L
More recommendations
Sector news : Pharmaceuticals - NEC
09/14NOVARTIS : Trial and Error -2-
DJ
09/14NOVARTIS : Trial and Error
DJ
09/14NOVARTIS : The Startup That Manipulated Data to Get a -2-
DJ
09/14NOVARTIS : The Startup That Manipulated Data to Get a Miracle Drug to Market
DJ
09/13SANOFI : FDA Finds Probable Carcinogen in Some Versions of Zantac --Update
DJ
More sector news : Pharmaceuticals - NEC
Chart CHUGAI PHARMACEUTICAL CO LTD
Duration : Period :
Chugai Pharmaceutical Co Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CHUGAI PHARMACEUTICAL CO L
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 12
Average target price 7 745,83  JPY
Last Close Price 7 500,00  JPY
Spread / Highest target 30,7%
Spread / Average Target 3,28%
Spread / Lowest Target -13,3%
EPS Revisions
Managers
NameTitle
Tatsuro Kosaka President, CEO & Representative Director
Osamu Nagayama Chairman
Itagaki Toshiaki CFO, Manager-Information Technology & Accounting
Hisafumi Okabe Senior Executive Officer & Head-Research
Hisanori Takanashi Manager-R&D Portfolio Management Department
Sector and Competitors
1st jan.Capitalization (M$)
CHUGAI PHARMACEUTICAL CO LTD21.36%37 983
JOHNSON & JOHNSON1.07%345 150
ROCHE HOLDING LTD.10.52%236 116
MERCK AND COMPANY8.11%211 513
PFIZER-15.44%204 151
NOVARTIS18.45%200 777